Compare TSQ & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSQ | MGNX |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 94.9M |
| IPO Year | 2000 | 2013 |
| Metric | TSQ | MGNX |
|---|---|---|
| Price | $5.34 | $1.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $12.50 | $3.20 |
| AVG Volume (30 Days) | 85.0K | ★ 1.4M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | ★ 15.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $438,695,000.00 | $127,626,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $4.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.30 | $0.99 |
| 52 Week High | $10.39 | $3.60 |
| Indicator | TSQ | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 45.93 |
| Support Level | $4.75 | $1.32 |
| Resistance Level | $4.98 | $1.47 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 89.00 | 41.30 |
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the premier local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and premier national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.